Shopping Cart
Remove All
Your shopping cart is currently empty
AM6545
😃Good
Catalog No. T22563Cas No. 1245626-05-4
Alias AM-6545, AM 6545
AM6545 is a selective and potent peripheral restricted cannabinoid receptor 1 (CB1) antagonist that inhibits the CB2 receptor, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate-induced obese mice, and may be useful in the study of obesity and diabetes.
AM6545
😃Good
Purity: 97.03%
Catalog No. T22563Alias AM-6545, AM 6545Cas No. 1245626-05-4
AM6545 is a selective and potent peripheral restricted cannabinoid receptor 1 (CB1) antagonist that inhibits the CB2 receptor, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate-induced obese mice, and may be useful in the study of obesity and diabetes.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $60 | In Stock | In Stock | |
| 5 mg | $158 | In Stock | In Stock | |
| 10 mg | $259 | - | In Stock | |
| 25 mg | $496 | - | In Stock | |
| 50 mg | $728 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97.03%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | AM6545 is a selective and potent peripheral restricted cannabinoid receptor 1 (CB1) antagonist that inhibits the CB2 receptor, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate-induced obese mice, and may be useful in the study of obesity and diabetes. |
| In vitro | METHODS: AM6545 (0.5 mM) was used to treat 3T3-L1 adipocytes to examine possible beiging effects of peripheral CB1R antagonist treatment, and the expression of key beiging markers was examined. RESULTS: AM6545 significantly increased many genes involved in adipocyte coagulation, including peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgc1α), PR domain containing 16 (Prdm16), and uncoupling protein 1 (Ucp1), cell death-inducing DNA fragmentation factor α-like effector A (Cieda), long-chain fatty acid protein 3 (Elovl3), tumor necrosis factor receptor superfamily member 9 (Cd137), T-box transcription factor ( Tbx1), transmembrane protein 26 (Tmem26), cbp/p300 interacting transactivator 1, fibroid/endoplasmic reticulum calcium 2+-ATPase 2b (Serca2b), ryanodine receptor 2 (Ryr2). [2] |
| In vivo | METHODS: AM6545 (1 mg/kg, intraperitoneal injection) and CNO (3 mg/kg) were administered to mice, and the discrimination index values of NORT in the vagus nerve were observed 48 hours after administration. RESULTS: AM6545 can improve memory consolidation through an adrenergic mechanism involving vagal afferent nerves. [1] |
| Synonyms | AM-6545, AM 6545 |
| Molecular Weight | 556.46 |
| Formula | C26H23Cl2N5O3S |
| Cas No. | 1245626-05-4 |
| Smiles | N#CCCC#CC=1C=CC(=CC1)C2=C(C(=NN2C3=CC=C(Cl)C=C3Cl)C(=O)NN4CCS(=O)(=O)CC4)C |
| Relative Density. | 1.31g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | DMSO: 5 mg/mL (8.99 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy AM6545 | purchase AM6545 | AM6545 cost | order AM6545 | AM6545 chemical structure | AM6545 in vivo | AM6545 in vitro | AM6545 formula | AM6545 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.